Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta
about
Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosisNew and emerging disease modifying therapies for multiple sclerosisDaclizumab for relapsing remitting multiple sclerosisDaclizumab for relapsing remitting multiple sclerosisDaclizumab for relapsing remitting multiple sclerosisMonoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomesMultiple sclerosis-a quiet revolutionDaclizumab therapy for multiple sclerosisReview of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosisTherapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosisThe shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapyPotassium channels, memory T cells, and multiple sclerosisTherapeutic decisions in multiple sclerosis: moving beyond efficacyDeoxyhypusine synthase promotes differentiation and proliferation of T helper type 1 (Th1) cells in autoimmune diabetesThe effects of interleukin-2 on immune response regulation.A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria.Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.Emerging therapies in multiple sclerosis.Daclizumab treatment for multiple sclerosis.Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach.Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosisT-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetesHow implementation of systems biology into clinical trials accelerates understanding of diseases.A novel monoclonal antibody specific for canine CD25 (P4A10): selection and evaluation of canine TregsFoxp3+ CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion.Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppressionLong-term daclizumab therapy in relapsing-remitting multiple sclerosis.Monoclonal antibodies in multiple sclerosis treatment: current and future steps.Safety of monoclonal antibodies for the treatment of multiple sclerosis.Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy.Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosisThrombotic microangiopathy in haematopoietic cell transplantation: an update.
P2860
Q21144329-E25EA0B8-053D-4FD7-91E4-D1A1D44CC83CQ22242305-746E24E9-04E8-4EF7-9A6A-D201CD0C1BDAQ24200496-B5197F35-135B-40BA-97B0-8DE79C5263F3Q24201637-4EF894C8-607F-47B0-8425-5789244140A1Q24234794-CE6FFBA4-A5FE-47FC-B4FE-69DC99BDCB0FQ26776234-BA2B1303-7C47-4578-99FB-D65ADB4A4CF7Q26826930-BE51DEBF-33BE-4E5E-BDB7-E6730CF666E0Q27022517-0AE5347F-4890-4FE1-AD40-EB19254F5A60Q27693249-1C004E1E-A587-46CE-857E-5C3760F2DA2EQ28066677-4D75D319-DC41-4F1B-8E7C-4A394627C771Q28088784-B77C5063-2699-4C20-B14B-F9552FA255A6Q28281365-C1CDC179-6C0F-4FC6-9F74-1437EE17AB6AQ28541039-7C20ABC1-0F0B-41AE-B2CD-45CB0FD12B2CQ28586190-E09A0637-7D9E-4176-B412-381D6E760155Q30252875-398AB299-A916-4B97-BA69-C73174E0C7C1Q30479825-FC8543E3-1EB6-4600-A94D-3B4B35B86CECQ30699740-D4A21BD3-A52C-41BB-A09C-F4A751CBAF02Q30730505-FF2C0243-CF64-4592-9D99-0E8A0138E0A4Q31015100-1CB0B817-E719-43EA-80AF-0EADBFD8C3EEQ33382919-0C93AD41-79C0-40D2-9C54-3FA230A3C8F8Q33534161-E45BDAF5-B166-4AC5-BF45-F85FFF9FC7E4Q33589947-251FFEFD-228C-4CD4-840E-0F4C8E400E87Q33723154-F15EA46D-370B-4869-96B5-9E90B3CBCCE0Q33751549-B6A32696-49B9-4FD2-A3A8-294099661E88Q33814843-A52925E9-AF40-4CBA-AC3C-272BD7D6FB89Q33830604-630BF965-342B-4D60-9CBC-56F9995477A7Q33932451-ECA55C92-4651-46A6-A915-B8BF04E754B7Q33965239-0E77A3B6-7556-41CC-9283-35CD4EFE7114Q34175958-A07FC0C9-BC39-4126-AC8A-ECC337EDABFFQ34409257-A083C127-2CD9-48F4-A187-2BB1ABA01E50Q34409404-37DA3953-0ADF-4507-B15C-E5553741E256Q34542922-C1828381-4DE5-406C-81A8-019753F45D9EQ34596171-1DC96009-4CB8-4915-A319-0C1BFF1610F5Q34630494-155C99E2-C27D-4326-BD72-46C381942203Q34893862-9A0C633D-9A53-440C-946A-810017E48D3AQ34893948-3514A383-49BF-433A-B3C5-9479B0A58AAEQ34949098-AC31C99F-563F-4BEB-8F18-9A52620266F6Q35012335-C02999A4-0611-420A-88D1-3F567A0EF458Q35091437-7C4E63B6-93E3-4073-A560-F9296E4F1074Q35098992-8D6DEE0F-F579-4120-9AF7-3D90FCAB3CE7
P2860
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Humanized anti-CD25 (daclizuma ...... to respond to interferon beta
@ast
Humanized anti-CD25 (daclizuma ...... to respond to interferon beta
@en
Humanized anti-CD25
@nl
type
label
Humanized anti-CD25 (daclizuma ...... to respond to interferon beta
@ast
Humanized anti-CD25 (daclizuma ...... to respond to interferon beta
@en
Humanized anti-CD25
@nl
prefLabel
Humanized anti-CD25 (daclizuma ...... to respond to interferon beta
@ast
Humanized anti-CD25 (daclizuma ...... to respond to interferon beta
@en
Humanized anti-CD25
@nl
P2093
P2860
P356
P1476
Humanized anti-CD25 (daclizuma ...... to respond to interferon beta
@en
P2093
Bibiana Bielekova
Gregg Blevins
Henry F McFarland
Jennifer McCartin
Jens Würfel
Joan Ohayon
Joseph A Frank
Nancy Richert
Roland Martin
Silva Markovic-Plese
P2860
P304
P356
10.1073/PNAS.0402653101
P407
P577
2004-05-25T00:00:00Z